The Clinical Features of Myositis-Associated Autoantibodies: a Review

被引:0
|
作者
Harsha Gunawardena
机构
[1] North Bristol NHS Trust,Clinical and Academic Rheumatology
[2] Southmead Hospital,undefined
关键词
Myopathy; Polymyositis; Dermatomyositis; Systemic sclerosis; Interstitial lung disease; Autoantibodies;
D O I
暂无
中图分类号
学科分类号
摘要
The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases traditionally defined by clinical manifestations including skeletal muscle weakness, skin rashes, elevated skeletal muscle enzymes, and neurophysiological and/or histological evidence of muscle inflammation. Patients with myositis overlap can develop other features including parenchymal lung disease, inflammatory arthritis, gastrointestinal manifestations and marked constitutional symptoms. Although patients may be diagnosed as having polymyositis (PM) or dermatomyositis (DM) under the IIM spectrum, it is quite clear that disease course between subgroups of patients is different. For example, interstitial lung disease may predominate in some, whereas cutaneous complications, cancer risk, or severe refractory myopathy may be a significant feature in others. Therefore, tools that facilitate diagnosis and indicate which patients require more detailed investigation for disease complications are invaluable in clinical practice. The expanding field of autoantibodies (autoAbs) associated with connective tissue disease (CTD)-myositis overlap has generated considerable interest over the last few years. Using an immunological diagnostic approach, this group of heterogeneous conditions can be separated into a number of distinct clinical phenotypes. Rather than diagnose a patient as simply having PM, DM or overlap CTD, we can define syndromes to differentiate disease subsets that emphasise clinical outcomes and guide management. There are now over 15 CTD-myositis overlap autoAbs found in patients with a range of clinical manifestations including interstitial pneumonia, cutaneous disease, cancer-associated myositis and autoimmune-mediated necrotising myopathy. This review describes their diagnostic utility, potential role in disease monitoring and response to treatment. In the future, routine use of these autoAb will allow a stratified approach to managing this complex set of conditions.
引用
收藏
页码:45 / 57
页数:12
相关论文
共 50 条
  • [1] The Clinical Features of Myositis-Associated Autoantibodies: a Review
    Gunawardena, Harsha
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2017, 52 (01) : 45 - 57
  • [2] ANTI-FHL1 AUTOANTIBODIES IN JUVENILE MYOSITIS ARE ASSOCIATED WITH MYOSITIS-ASSOCIATED AUTOANTIBODIES BUT NOT DISTINCTIVE CLINICAL FEATURES
    Sherman, Matthew A.
    Graf, Rose
    Galindo-Feria, Angeles S.
    Sabbagh, Sara E.
    Pinal-Fernandez, Iago
    Pak, Katherine
    Kishi, Takayuki
    Targoff, Ira N.
    Miller, Fred-Erick W.
    Lundberg, Ingrid E.
    Rider, Lisa G.
    Mammen, Andrew L.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 480 - 481
  • [3] Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality
    Sherman, Matthew
    Farhad, Payam Noroozi
    Pak, Katherine
    Pinal-Fernandez, Iago
    Sarkar, Kakali
    Neely, Megan
    Targoff, Ira
    Miller, Frederick
    Mammen, Andrew
    Rider, Lisa
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3216 - 3218
  • [4] Update on myositis-specific and myositis-associated autoantibodies
    Targoff, IN
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (06) : 475 - 481
  • [5] Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis
    Puja Srivastava
    Sanjay Dwivedi
    Ramnath Misra
    [J]. Rheumatology International, 2016, 36 : 935 - 943
  • [6] Myositis-Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality
    Sherman, Matthew A.
    Farhadi, Payam Noroozi
    Pak, Katherine
    Trieu, Edward P.
    Sarkar, Kakali
    Targoff, Ira N.
    Neely, Megan L.
    Mammen, Andrew L.
    Rider, Lisa G.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2024, 76 (06) : 963 - 972
  • [7] Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis
    Srivastava, Puja
    Dwivedi, Sanjay
    Misra, Ramnath
    [J]. RHEUMATOLOGY INTERNATIONAL, 2016, 36 (07) : 935 - 943
  • [8] Clinical Features And Prognostic Factors Of Myositis-Associated Interstitial Lung Diseases
    Fujisawa, T.
    Hozumi, H.
    Kono, M.
    Karayama, M.
    Hashimoto, D.
    Enomoto, N.
    Nakamura, Y.
    Inui, N.
    Yokomura, K.
    Koshimizu, N.
    Toyoshima, M.
    Shirai, T.
    Suda, T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [9] Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis
    Gupta, Latika
    Naveen, R.
    Gaur, Priyanka
    Agarwal, Vikas
    Aggarwal, Rohit
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2021, 51 (01) : 113 - 120
  • [10] Prevalence of Myositis-Specific Autoantibodies and Myositis-Associated Autoantibodies in COVID-19 Patients: A Pilot Study and Literature Review
    Swartzman, Isaac
    Gu, Juan J.
    Toner, Zachary
    Grover, Raminder
    Suresh, Lakshmanan
    Ullman, Lori E.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)